| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Biotechnology
| Regeneron is actively pursuing product and service development, which has been highlighted by ongoing advancements in healthcare showcased at various conferences. However, the recent failures in clinical trials, particularly those related to the melanoma treatment fianlimab, have raised significant concerns regarding its product pipeline. These setbacks have had a notably negative impact on the company's stock performance and market perception. While some aspects of product development remain promising, the failures reveal critical challenges that must be addressed for future success. |
| The price action of Regeneron Pharmaceuticals (REGN) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -4.2 is extremely bearish. The market sentiment at -1.1 is very bearish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. REGN is likely to move down since both trend sentiment and market sentiment are negative. The positive sentiment force for sector is at 0.5, and the negative at -1.6 on 2026-05-18. The forces of Stock Price Trend (-4.2), Sentiment towards Fundamentals (-2), Valuation Sentiment (-1.5), Sector Price Trend (-1.5), and Market Risk Appetite (-0.9) will drive down the price. The forces of Price Level Sentiment (1.5), and Option Sentiment (1.5) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| REGN | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | 0%(0%) | 629.36 | 4.51% | -27 | -9.87% | -1.12% | -4.2 | -1.6 | 6.3% | -1.1 | Wait | 50% | -2 | -8 |
| 2026-05-17 | 0%(0%) | -0.9 | -1.6 | -0.3 | 1.2 | -1 | ||||||||
| 2026-05-16 | 0%(0%) | -0.9 | -1.6 | -0.3 | 1.2 | -1 | ||||||||
| 2026-05-15 | 0%(0%) | 698.25 | 3.01% | 21 | -2% | -0.04% | -0.9 | -0.3 | 1.3% | 0 | Short | 55% | 1.5 | -1 |
| 2026-05-14 | 0%(0%) | 712.52 | 2.96% | 35 | -1.02% | 0.07% | 0 | -0.3 | 0.4% | 0.3 | Short | 55% | 1.5 | -1 |
| 2026-05-13 | 0%(0%) | 719.88 | 2.96% | 42 | -0.49% | 0.48% | 0.3 | 0.2 | 0.8% | 0.3 | Long | 55% | 0.8 | -1 |
| 2026-05-12 | 0%(0%) | 723.41 | 3.05% | 44 | 1.54% | -0.13% | 0.3 | 0.5 | 0.8% | 0.9 | Long | 55% | 0.9 | -1 |
| 2026-05-11 | 0%(0%) | 712.43 | 3.19% | 30 | -0.34% | -0.45% | -0.6 | -0.1 | 0.7% | 0.9 | Short | 55% | 1.1 | -1 |
| 2026-05-10 | 0%(0%) | -0.3 | -0.1 | 0.8 | 2.1 | -1 | ||||||||
| 2026-05-09 | 0%(0%) | -0.3 | -0.1 | 0.8 | 2.1 | -1 | ||||||||
| Wait is the preferred trading strategy with 50% chance of being right. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| 2026-05-18 17:48:59 The failure of the fianlimab drug trial reflects challenges in product development and may affect future innovations at Regeneron. |
| 2026-05-18 17:48:59 The trial failure puts Regeneron in a competitive disadvantage against Merck's Keytruda, highlighting the challenges in the oncology market. |
| 2026-05-18 17:48:59 The decline in Regeneron's stock price following the failure of its key drug trial demonstrates a negative impact on investor sentiment. |
| 2026-05-18 17:08:38 Investigation into possible securities violations and the impact of failed clinical trials raises concerns about regulatory scrutiny and legal challenges for Regeneron. |
| 2026-05-18 17:08:38 Despite setbacks, Regeneron announced strategic collaborations aimed at advancing their drug development capabilities, indicating potential for future growth. |
| 2026-05-18 17:08:38 Following the disappointing trial results, several analysts downgraded Regeneron, impacting investor sentiment and market perception of the company. |
| 2026-05-18 17:08:38 Regeneron’s stock has faced significant declines following negative trial results, prompting discussion about its market position and future prospects. |
| 2026-05-18 17:08:38 Multiple articles detail the failure of Regeneron's treatment in clinical trials for melanoma, leading to significant drops in stock performance and negative analyst reactions. |
| 2026-05-18 13:48:32 Regeneron faces intensified competition from Merck's Keytruda as a result of its trial failure, affecting its position in the melanoma treatment market. |
| 2026-05-18 13:48:32 Regeneron's stock sees a noticeable decline following the unsuccessful trial, indicating investor concerns and market reactions. |
| 2026-05-18 13:48:32 The failure of Regeneron's late-stage trial for fianlimab, a melanoma drug, significantly impacts the company's product pipeline and stock performance. |
| 2026-05-18 11:48:52 Regeneron faces significant competition from Merck's Keytruda, which highlights the challenges in the competitive landscape of melanoma treatments. |
| 2026-05-18 11:48:52 The failure of the drug trial resulted in a notable decrease in Regeneron's stock value. |
| 2026-05-18 11:48:52 The failure of the melanoma drug trial for Regeneron's fianlimab leads to a significant negative impact on the company's stock. |
| 2026-05-18 09:36:18 The drop in Regeneron's stock price reflects investor concerns over the company's ability to deliver successful products. |
| 2026-05-18 09:36:18 The failure of the fianlimab-cemiplimab combination to meet trial goals indicates major challenges in product development for Regeneron. |